Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palisade Bio Inc.

1.00
+0.08258.99%
Post-market: 0.9350-0.0650-6.50%19:57 EDT
Volume:1.46M
Turnover:1.48M
Market Cap:2.77M
PE:-0.07
High:1.10
Open:0.9600
Low:0.9536
Close:0.9175
Loading ...

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of Pali-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (Uc)

THOMSON REUTERS
·
07 Nov 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

GlobeNewswire
·
07 Nov 2024

Palisade Bio Announces Positive Data From Two Ex Vivo Translational Studies of Pali-2108 for the Treatment of Ulcerative Colitis

THOMSON REUTERS
·
31 Oct 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire
·
31 Oct 2024

Palisade Bio Files for Public Offering of Shares, Warrants

MT Newswires Live
·
30 Oct 2024

Palisade Bio Gets Health Canada Clearance to Start Phase 1 Study of PALI-2108 for Treating Ulcerative Colitis

MT Newswires Live
·
10 Oct 2024

BRIEF-Palisade Bio Cleared By Health Canada To Commence Phase 1 Clinical Study

Reuters
·
10 Oct 2024

Palisade Bio Inc - on Track Commence Site Initiation and Enrollment for Study Before Year End

THOMSON REUTERS
·
10 Oct 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, Pali-2108 for the Treatment of Ulcerative Colitis (Uc)

THOMSON REUTERS
·
10 Oct 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

GlobeNewswire
·
10 Oct 2024

BRIEF-Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, Pali-2108 For The Treatment Of Ulcerative Colitis

Reuters
·
25 Sep 2024

Palisade Bio: on Track Towards Clinical Site Initiation and Dosing of First Patient in Phase 1 Human Clinical Study Before Year End

THOMSON REUTERS
·
25 Sep 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, Pali-2108 for the Treatment of Ulcerative Colitis

THOMSON REUTERS
·
25 Sep 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire
·
25 Sep 2024

Palisade Bio - Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

THOMSON REUTERS
·
16 Sep 2024